Harry Thomasian, Jr. net worth and biography

Harry Thomasian, Jr. Biography and Net Worth

CFO of Precigen
Mr. Harry Thomasian Jr. serves as the Chief Financial Officer for Precigen. Mr. Thomasian is a global finance leader with over 35 years of international business experience in equity and debt financings, P&L management and business operations, regulatory compliance and generally accepted accounting principles, SEC filings and Sarbanes-Oxley compliance. Prior to joining the company, Mr. Thomasian was with EY (formerly Ernst & Young LLP), one of the world’s largest global professional services firms. He most recently served as Senior Client Services Partner and the Baltimore Office Growth Markets Leader for the life sciences industry and Senior Partner in EY’s Capital Markets Center in Tokyo as well as other various global, area and local leadership positions. Mr. Thomasian earned a BS in Accountancy from Bentley University and completed the Ernst & Young Executive Development Program at the Kellogg School of Management, Northwestern University. Mr. Thomasian is licensed as a certified public accountant by the State Boards of Accountancy in Maryland, North Carolina, Washington, DC and Virginia.

How do I contact Harry Thomasian, Jr.?

The corporate mailing address for Mr. Thomasian, Jr. and other Precigen executives is 20374 Seneca Meadows Parkway, Germantown MD, 20876. Precigen can also be reached via phone at (301) 556-9900 and via email at [email protected] Learn More on Harry Thomasian, Jr.'s contact information.

Has Harry Thomasian, Jr. been buying or selling shares of Precigen?

Harry Thomasian, Jr. has not been actively trading shares of Precigen over the course of the past ninety days. Learn More on Harry Thomasian, Jr.'s trading history.

Who are Precigen's active insiders?

Precigen's insider roster includes Randal Kirk (Director), Donald Lehr (Insider), David Obstler (CFO), Jeffrey Perez (SVP), Helen Sabzevari (CEO), and Harry Thomasian, Jr. (CFO). Learn More on Precigen's active insiders.

Are insiders buying or selling shares of Precigen?

In the last year, Precigen insiders bought shares 4 times. They purchased a total of 564,665 shares worth more than $2,045,188.11. In the last year, insiders at the biotechnology company sold shares 17 times. They sold a total of 558,600 shares worth more than $1,715,260.13. The most recent insider tranaction occured on August, 23rd when CFO Harry Jr. Thomasian bought 24,500 shares worth more than $51,205.00. Insiders at Precigen own 43.7 % of the company. Learn More about insider trades at Precigen.

Information on this page was last updated on 8/23/2022.

Harry Thomasian, Jr. Insider Trading History at Precigen

See Full Table

Harry Thomasian, Jr. Buying and Selling Activity at Precigen

This chart shows Harry Jr. Thomasian's buying and selling at Precigen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Precigen Company Overview

Precigen logo
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Read More

Today's Range

Now: $2.18
Low: $2.14
High: $2.27

50 Day Range

MA: $2.30
Low: $1.68
High: $2.79

2 Week Range

Now: $2.18
Low: $1.12
High: $5.60

Volume

35,566 shs

Average Volume

1,119,975 shs

Market Capitalization

$453.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.1